ACRO Holds Initial Meeting of CRO Forum, Begins Two-Way Dialogue With TransCelerateMarch 9, 2015 2:06 pm
March 9, 2015 – WASHINGTON, DC – The Association of Clinical Research Organizations, whose members account for approximately two-thirds of contract clinical development services, held the inaugural meeting of the previously announced CRO Forum in Washington, DC. The Forum was established in October 2014 as the primary vehicle for interaction between the CRO industry and TransCelerate BioPharma Inc.
The Forum elected as its first Chairman Dr. Alan Metz, Senior Vice President and Managing Director, Strategic Partnerships, at Quintiles. As Vice Chair, the Forum elected Amy Kissam, Executive Director, Global Operational Management, at INC Research.
ACRO and TransCelerate have mutually agreed to initially establish liaison relationships between four TransCelerate workstreams: risk-based monitoring; shared site qualification and training; common protocol template; and quality management system. The Forum selected senior subject matter experts to serve as liaisons to each of these workstreams. The liaisons will be supported by working groups consisting of subject matter experts from across the Forum membership.
“With the ever-increasing role CROs are playing across the drug development spectrum, and the innovation we are bringing to the process, we look forward to entering a meaningful dialogue with TransCelerate,” said ACRO Chairman Jamie Macdonald, CEO of INC Research. “As the relationship progresses, we anticipate providing CRO industry input into additional workstreams as well as suggesting possible new workstreams for TransCelerate’s consideration.”
All members of ACRO participate in the Forum and non-member CROs may take part for a modest membership fee. CROs interested in participating in the Forum may contact ACRO via email at: CROForum@acrohealth.org.
About ACRO The Association of Clinical Research Organizations (ACRO) represents companies that provide a variety of specialized services that support the development of new pharmaceuticals, biologics, and medical devices. The Association provides an active voice for the CRO industry globally. Through its member companies, ACRO helps improve the quality, efficiency and safety of biomedical research. ACRO member companies employ more than 110,000 professionals worldwide, conduct research in 142 countries and contribute to the development of approximately 95% percent of all new drugs and biologics approved globally. For more information, please visit www.acrohealth.org. Twitter @acrohealth. YouTube @ACROHealthChannel. Facebook.RebelMouse.